Navigation Links
Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging
Date:6/15/2010

BERLIN and BERGISCH GLADBACH, Germany, June 16, 2010 /PRNewswire/ -- Miltenyi Biotec today announces the worldwide release of the Viscover(TM) product line, offering researchers an unrivaled range of preclinical contrast agents for small animal in vivo imaging.

Viscover marks the result of a fruitful collaboration between Miltenyi Biotec GmbH and nanoPET Pharma GmbH. Within this strategic alliance, Miltenyi Biotec is responsible for the distribution of Viscover products developed and manufactured by nanoPET Pharma. The current Viscover portfolio comprises twenty-one contrast agents for the preclinical imaging modalities MRI, CT, Optical Imaging, Ultrasound and SPECT/PET, and this number is set to increase soon.

"This partnership offers researchers a unique and powerful portfolio of small animal in vivo imaging agents," explains Stefan Miltenyi, CEO of Miltenyi Biotec. "Both nanoPET Pharma and Miltenyi Biotec are committed to serving the biomedical research community with innovative high-quality imaging products throughout the world."

Commenting on the collaboration, Andreas Briel, CEO of nanoPET Pharma GmbH, said: "This landmark partnership brings together Miltenyi Biotec's excellence in worldwide customer support with nanoPET's exclusive range of contrast agents. Our scientists have years of experience in biomedical imaging, gained through strong affiliations with commercial and academic bodies."

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding and medical progress by providing products and services for cellular therapies. With approx. 1100 employees in 18 countries, Miltenyi Biotec develops, manufactures, and commercializes innovations for both research and clinical applications. The portfolio provides integrated solutions for all areas covering sample preparation, cell separation, cell culture, flow cytometry, and molecular analysis.

Visit http://www.miltenyibiotec.com to learn more.

About nanoPET Pharma

Based in Berlin, nanoPET Pharma GmbH discovers and develops innovative pharmaceutical contrast agents for use with the complete range of preclinical imaging modalities. The comprehensive Viscover portfolio currently provides contrast agents for the MRI, CT, Ultrasound, Optical Imaging, SPECT and PET modalities.

    Visit http://www.viscover.com to discover more.

    Contact:

    Miltenyi Biotec
    Prof. Dr. Uwe Heinlein, Corporate Communications,
    Miltenyi Biotec GmbH, +49-2204-8306-6590,
    uweh@miltenyibiotec.de

    nanoPET Pharma
    Carolin Schlueter, Corporate Communications,
    nanoPET Pharma GmbH, +49-30-890-49-740,
    Carolin.Schlueter@nanopet.de


'/>"/>
SOURCE Miltenyi Biotec GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... plc (NASDAQ: ENDP ) will announce its second-quarter 2017 ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 45397076. Please dial in 10 minutes prior to the scheduled start ... the call will be available from August 8, 2017 at 11:30 ...
(Date:7/13/2017)... July 13, 2017 RK Logistics Group, Inc. was ... certification for its Fremont, CA headquarters ... the Tri-Valley and San Jose for ... of Fremont , with its Fremont Innovation District, is ... such a powerful resource to the hundreds of biotech, pharma ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
Breaking Medicine Technology:
(Date:7/24/2017)... , ... July 24, 2017 , ... A CDC study shows that, although people are ... Caucasians (ages 18 to 29), had at least one case of sunburn within the past ... which causes people to ignore the issue. However, only recently have people become conscientious of ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 NCSL International Workshop ... theme focuses on the new ISO/IEC 17025 standards. This marks the first time ... and calibration will be changed. , As an exhibitor, METTLER TOLEDO will ...
(Date:7/24/2017)... ... July 24, 2017 , ... Paul Vitenas, MD, FACS is excited ... plastic surgeons, invited to attend Allergan’s recent meeting with their Plastics Advisory Board. As ... the world, Allergan is bringing a newly defined structure to the aesthetics market. ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... CURE announced that they have enrolled over 100,000 children in their treatment program. ... born every year in areas where treatment is limited or non-existent. Without intervention, ...
(Date:7/24/2017)... Church, VA (PRWEB) , ... July 24, 2017 ... ... figuring out how to change manufacturers future. , The agency is hammering out ... Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. The ...
Breaking Medicine News(10 mins):